Fig. 1. Transfection of RPL9 siRNA reduces the metastatic potential of parental CRC cell population. (A, B) Representative light microscopy images and relative percentage of invasive (A) and migratory (B) HT29 and HCT116 cells treated with NC siRNA or RPL9 siRNA. Numbers of invaded and migrated cells were stained with crystal violet, counted, and graphed. Scale bar, 100 μm. (C) Detection of sphere formation in HT29 cells treated with NC siRNA or RPL9 siRNA. The differences in sphere forming capacity were compared by calculating both size and number of spheres. NC siRNA, negative control siRNA; RPL9 siRNA, RPL9-specific siRNA. Statistical significance: *P < 0.05; **P < 0.01; ***P < 0.001 vs. NC siRNA treatment. RPL9, ribosomal protein L9; CRC, colorectal cancer; NC, negative control.

© J Cancer Prev